Evidence map›Paper›PMID 36643727›Full record

ArticleAtherosclerosis plus2021

Hypoglycemia-induced changes in complement pathways in type 2 diabetes.

Abu Saleh Md Moin, Manjula Nandakumar, Ilhame Diboun, Ahmed Al-Qaissi, Thozhukat Sathyapalan, Stephen L Atkin, Alexandra E Butler

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Atherosclerosis plus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03102801 (A Study to Identify Biomarkers of Hypoglycaemia in Patients With Type 2 Diabetes), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03102801 nacompletednot on this map

A Study to Identify Biomarkers of Hypoglycaemia in Patients With Type 2 Diabetes

TypeinterventionalSponsorUniversity of HullRan2017 to 2018Enrolled50ConditionsType 2 Diabetes Mellitus With HypoglycemiaArmsHumulin S
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Abu Saleh Md MoinDiabetes Research Center (DRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha, Qatar.
Manjula NandakumarDiabetes Research Center (DRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha, Qatar.
Ilhame DibounHamad Bin Khalifa University (HBKU), Doha, Qatar.
Ahmed Al-QaissiAcademic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK.
Thozhukat SathyapalanAcademic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK.
Stephen L AtkinRoyal College of Surgeons in Ireland Bahrain, Adliya, Bahrain.
Alexandra E ButlerRoyal College of Surgeons in Ireland Bahrain, Adliya, Bahrain.
Hamad bin Khalifa University · QAHull York Medical School · GBRoyal College of Surgeons in Ireland - Bahrain · BH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: An association between hypoglycaemia and adverse cardiovascular events has been suggested from longitudinal and retrospective cohort studies. The complement pathway proteins in hypoglycemia are not well studied. Here, we hypothesized that these circulating proteins would be elevated in response to hypoglycemia in type 2 diabetes (T2D) through the inflammatory response. Methods: A prospective, parallel study in T2D (n = 23) and controls (n = 23). Subjects underwent insulin-induced hypoglycemia with blood sampling at baseline, hypoglycemia and post-hypoglycemia; SOMAscan proteomic analysis of complement pathway-related proteins, cytokines and inflammatory proteins was undertaken. Results: At baseline: Complement C2 (p < 0.05) and Factor B (p < 0.05) were elevated in T2D. At hypoglycemia: Complement C2 (p < 0.05) and Factor B (p < 0.01) remained elevated, whilst Factor I became elevated (p < 0.05) in T2D; Complement C4b became elevated in controls (p < 0.05). In the post-hypoglycemia follow up period, Complement C2, Factor B and Factor I remained elevated in T2D; in addition, Factor D, Factor H and mannose-binding protein C showed elevations in T2D, whilst properdin, complement C3b, Factor H-related protein 5, complement C1q and decay-accelerating factor (DAF) showed elevations in controls. Granger causality analysis showed that inflammatory proteins appeared to drive complement protein changes in T2D; conversely, in controls, complement proteins drove inflammatory protein changes. Conclusions: Baseline elevations in C2 and Factor B indicate upregulation of the complement pathway in T2D. Changes in complement pathway-related protein levels in response to hypoglycemia suggest both intrinsic and alternative pathway activation at 2-h that appears driven by the underlying inflammation in T2D and could contribute to a cardiovascular event.ClinicalTrials.gov NCT03102801. Date of registration April 6, 2017, retrospectively registered. https://clinicaltrials.gov/ct2/show/NCT03102801?term=NCT03102801&draw=2&rank=1.

Indexed as

Complement proteinsHypoglycemiaProteomicsType 2 diabetes

Identifiers

PMID36643727
PMCPMC9833243
OpenAlexW3215288605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.